RAMP3 was already known to cancer biologists as a player in stromal regulation, the management of the non-cancerous scaffolding tissue that surrounds and supports tumors. What remained murky was its role in remodeling the tumor microenvironment, the complex ecosystem of immune cells, fibroblasts, blood vessels and signaling molecules in which tumors live, and in shaping resistance to immune checkpoint blockade. The Shinshu team set out to answer two questions: whether RAMP3 actively shapes an immunosuppressive tumor microenvironment, and whether blocking it could improve responses to immunotherapy. Their strategy combined direct genetic manipulation in mice with high-resolution molecular atlasing of the resulting tumors, an approach that allows researchers to move beyond correlation and establish functional cause and effect.

The experimental core of the study was a set of syngeneic mouse models of breast cancer, in which tumors are transplanted into mice with intact immune systems, making them far more faithful stand-ins for human cancer than immunodeficient models. By genetically deleting RAMP3, the researchers could watch what happened to tumor progression, immune composition and therapeutic response. The results were striking. Loss of RAMP3 suppressed primary tumor growth, reduced the spread of cancer to the lungs, and significantly improved survival. These were not subtle shifts in cell culture dishes; they were whole-animal outcomes measured in vivo, which lends considerable weight to the biological relevance of the molecule.

To understand how removing a single protein could produce such dramatic effects, the team turned to single-cell RNA sequencing, a technique that profiles the gene activity of thousands of individual cells within a tumor, allowing researchers to identify every immune cell type present and the precise states those cells occupy. The analysis revealed a fundamental reprogramming of the tumor immune landscape. In tumors lacking RAMP3, the balance of tumor-associated macrophages, the abundant scavenger cells that tumors often corrupt into allies, shifted away from M2-like states, which are classically immunosuppressive and wound-healing in character, toward antigen-presenting macrophage states that display tumor fragments to the immune system and sound the alarm. At the same time, the researchers observed increased infiltration of CD8-positive T cells, the cytotoxic soldiers that directly kill cancer cells, along with a reduction in T cell exhaustion, the dysfunctional state that renders T cells impotent in immunosuppressive environments.

The mechanistic thread connecting these changes appears to run through a well-known immune signaling pathway. RAMP3 deficiency was associated with reduced IL-4/STAT6 signaling in macrophages. Interleukin-4 signaling through the STAT6 transcription factor is a canonical driver of M2-like macrophage polarization, so damping this pathway helps explain why macrophages in RAMP3-deficient tumors adopted a more immune-activating identity. Downstream of this shift, the researchers found decreased expression of immunosuppressive genes, most notably the chemokine CCL8, a signaling molecule that recruits and organizes cells within the tumor microenvironment. Chemokines act as molecular addresses, and CCL8 appears to be one of the addresses that helps assemble an immune-excluded architecture favorable to tumor growth.

Crucially, the team did not rely on genetics alone to make this point. When they pharmacologically inhibited the synthesis of CC chemokines, the drug treatment reproduced the effects of RAMP3 deletion, providing independent evidence that the CCL8-centered chemokine circuit is a functional driver of the immunosuppressive environment rather than a mere bystander. Spatial transcriptomic analysis, which maps gene expression onto physical locations within tissue, added a geographic dimension to the story: RAMP3 and CCL8 were found to be co-localized within the tumor microenvironment, suggesting that the two molecules operate together in the same tumor neighborhoods where immune exclusion takes place.

Perhaps the most clinically consequential finding concerns immunotherapy itself. PD-1 blockade works by releasing the molecular brakes on T cells, but it can only succeed if functional T cells are present in the tumor in the first place. In tumors where macrophages have walled off the immune system, checkpoint inhibitors have little to work with. The Shinshu researchers showed that RAMP3 deficiency enhanced the efficacy of PD-1 blockade in their mouse models, effectively converting a resistant tumor into one that responds to treatment. This positions RAMP3 not simply as another tumor suppressor or oncogene, but as a regulator of immunotherapy sensitivity, a category of target that has become one of the most sought-after prizes in translational oncology.

To test whether these mouse findings translate to human disease, the team analyzed data from The Cancer Genome Atlas breast cancer cohort, known as TCGA-BRCA, one of the largest publicly available collections of human tumor genomic and clinical data. They constructed a weighted risk score combining RAMP3 with CD163, a marker of M2-like macrophages, and CD8A, a marker of cytotoxic T cells, capturing the triad of molecular features their mouse work had implicated. Patients with a higher score had significantly poorer overall survival. Importantly, the association held up in complete-case multivariable Cox models adjusted for clinicopathological variables, meaning the RAMP3-associated signature carried prognostic information beyond standard clinical measures such as tumor stage and grade. This kind of cross-species validation, in which a mechanism discovered in mice leaves a detectable fingerprint in human survival data, is exactly the standard that promising therapeutic targets must meet.

The study also exemplifies a broader methodological trend reshaping cancer research. Rather than examining tumors through a single lens, the researchers integrated in vivo genetics, single-cell transcriptomics, spatial transcriptomics and human cohort analysis into one coherent narrative. Each technique compensates for the blind spots of the others: mouse models establish causality but may not fully recapitulate human disease; single-cell sequencing reveals cell states but loses spatial context; spatial transcriptomics restores geography but at lower resolution; and human datasets provide clinical relevance but only correlation. Weaving these threads together, the authors built a case for RAMP3 that is considerably stronger than any single approach could deliver.

Significant work remains before RAMP3 reaches the clinic. The study was conducted in mice and validated against retrospective human data; prospective clinical trials targeting the RAMP3 pathway in breast cancer patients have yet to be conducted, and the precise molecular partners through which RAMP3 acts, including its role as an accessory protein for receptor systems, will require further mechanistic dissection. Nevertheless, the convergence of evidence is compelling. A molecule that was, until now, a footnote in stromal biology has emerged as a plausible regulator of the immunosuppressive tumor microenvironment, a determinant of macrophage identity, a gatekeeper of T cell infiltration, and a modifier of PD-1 blockade response. If pharmacological strategies can be developed to inhibit RAMP3 function or its downstream CCL8-driven chemokine circuit in human tumors, the researchers suggest it could open a path to overcoming checkpoint resistance in a cancer type that has largely stood apart from the immunotherapy revolution. For the many breast cancer patients whose tumors exclude immune cells and resist PD-1 inhibitors, that path, however early, is one worth watching closely.

Subject of Research: The role of RAMP3 in macrophage-driven immune exclusion and resistance to PD-1 blockade in breast cancer

Article Title: RAMP3 is associated with macrophage-driven immune exclusion and promotes resistance to PD-1 blockade in breast cancer: integrated in vivo and single-cell transcriptomic analyses

Article References: Zhang, Y., Tanaka, M., Sakurai, T., Kamiyoshi, A., Ichikawa-Shindo, Y., Guo, Q., Hoshiyama, K., Li, P., Li, J., Duan, J., Hayashi, M., Kai, K., Zhao, Y., Dai, K., & Shindo, T. (2026). RAMP3 is associated with macrophage-driven immune exclusion and promotes resistance to PD-1 blockade in breast cancer: integrated in vivo and single-cell transcriptomic analyses. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09001-4

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09001-4

Keywords: RAMP3, breast cancer, tumor microenvironment, tumor-associated macrophages, PD-1 blockade, immune checkpoint resistance, CCL8, IL-4/STAT6 signaling, single-cell RNA sequencing, spatial transcriptomics, CD8-positive T cells, TCGA-BRCA

The pipeline begins with one of the most detailed single-cell RNA sequencing atlases of triple-negative breast cancer available, dataset GSE176078, which profiles more than 100,000 cells from 26 treatment-naive patients. After rigorous quality control that removed cells with excessive mitochondrial content or too few detected genes, the researchers normalized expression data, identified 2,000 highly variable genes, and applied principal component analysis, k-nearest neighbor graph construction, and Leiden clustering to organize the cellular landscape. The resulting atlas resolved nine major cell compartments, including T cells, myeloid cells, B cells, cancer epithelial cells, and cancer-associated fibroblasts. Validation against the curated reference annotations produced adjusted rand index values between 0.288 and 0.311 and normalized mutual information values between 0.616 and 0.671, confirming that the unsupervised clustering substantially recovered known biology despite the inherent difficulty of matching 35 data-driven clusters to nine curated labels.

With the atlas established, the analysis zeroed in on the T cell compartment, extracting roughly 15,000 to 30,000 T cells and re-processing them independently to resolve functional sub-states. Two gene-set module scores quantified exhaustion and cytotoxicity across the population. The centerpiece of the study, however, is a deceptively simple quantity: the per-cell ratio of PDCD1, the gene encoding the inhibitory receptor PD-1, to CD2, the adhesion receptor that stabilizes the immune synapse between T cells and their targets. When PD-1 expression dominates and CD2 is low, inhibitory signaling suppresses activation so thoroughly that even dense CD58 ligand on an opposing surface cannot overcome it. When CD2 is moderately expressed but PD-1 only mildly elevated, calibrated CD2/CD58 ligand density can restore synapse stability and partial T cell activation. Prior work had shown that CD2 expression on tumor-infiltrating CD8 T cells correlates negatively with exhaustion markers and that CD2/CD58 co-stimulation is less sensitive to PD-1 inhibition than canonical CD28 signaling.

Aggregating these measurements per patient revealed three distinct immune phenotypes across the cohort. Roughly eight patients formed a high-exhaustion group in which more than 65 percent of CD8 T cells were classified as exhausted and PD-1 expression exceeded CD2 by three-and-a-half to five-fold. Their cells showed the lowest cytotoxic scores, consistent with a terminally exhausted state in which effector function is epigenetically silenced, making CD2-directed surface engineering alone an insufficient strategy. A second group of about ten patients retained measurable cytotoxic capacity alongside moderate exhaustion; their principal barrier appeared to be inadequate synapse stabilization rather than irreversible transcriptional shutdown, making them the most tractable candidates for calibrated CD2/CD58 ligand density optimization. A third group of roughly eight patients showed sparse CD8 infiltration altogether, representing immune-cold tumors where T cell recruitment must precede any activation engineering. Across all patients, mean PDCD1 expression spanned a seven-fold range and the resulting PDCD1/CD2 ratios ranged from approximately 0.3 to 4.1, capturing clinically meaningful variability invisible to bulk gene expression summaries.

To test whether the ratio carries clinical weight beyond the single-cell cohort, the team turned to TCGA-BRCA bulk RNA sequencing data of roughly 1,100 samples. In unadjusted Cox regression, higher bulk PDCD1/CD2 ratios were associated with lower mortality, with a hazard ratio of 0.47 and a confidence interval of 0.28 to 0.79, reaching statistical significance below 0.005. That direction appears paradoxical at first, since a high ratio reflects exhaustion at the single-cell level. The authors are careful to explain the discrepancy: in bulk tissue, PDCD1 transcripts derive from the entire immune infiltrate rather than from exhausted CD8 cells alone, so a high bulk ratio primarily signals strong immune infiltration, itself a favorable prognostic factor in breast cancer. This cell-type composition effect inverts the ratio’s meaning across measurement platforms, and the study explicitly frames the survival association as exploratory and hypothesis-generating rather than as validation of a clinical biomarker.

Cross-modal comparison of the 24 patients with matched bulk and single-cell data reinforced this interpretation with appropriate caution. Spearman correlations between single-cell-derived and bulk-derived ratios were weakly negative at approximately minus 0.30, consistent with the infiltration confound compressing the denominator, while exhaustion scores showed a weakly positive correlation of about 0.28, directionally consistent with the hypothesis that higher single-cell exhaustion burden corresponds to higher bulk exhaustion signal. Neither correlation reached conventional statistical significance given the small matched sample, but the directional agreement across platforms suggests the single-cell signals are not artifacts of normalization. Kaplan-Meier analysis stratified by the bulk ratio median showed longer median overall survival in the high-ratio group, with median survival differences of roughly 12 to 18 months and curve separation emerging after about two years of follow-up.

Beyond stratification, the pipeline delivers what previous tools have not: engineering output. A targeted ligand-receptor proxy screen across five immune axis pairs placed PD-1/PD-L1 highest in both T cell-tumor and T cell-myeloid pairings, reflecting the co-elevation of PD-1 on exhausted T cells and PD-L1 across tumor and myeloid compartments. CD2/CD58 ranked moderately at the tumor interface but low with myeloid cells, indicating that CD2-directed ligand optimization is specific to the direct tumor-T cell boundary. LAG-3/HLA-DRA showed the inverse profile, strongest with myeloid and B cell ligand sources, while CD28 co-stimulation was broadly downregulated throughout the tumor microenvironment, consistent with exhaustion-associated loss of CD28 expression. The authors emphasize these rankings are comparative heuristics from product-of-means calculations, not statistically validated communication events, and require experimental confirmation through co-culture or blocking assays.

The final translation step is the DesignPriorityScore, a rule-based metric combining normalized exhaustion burden with 50 percent weight, PDCD1/CD2 axis imbalance with 30 percent weight, and CD8 infiltration with 20 percent weight. Each of the 26 patients receives a ranked score and a corresponding recommendation: recruitment-first strategies for immune-desert tumors, combined PD-1 blockade with CD2 reinforcement for the highest-exhaustion group, CD2/CD58 axis optimization for the moderate group, and CD28 co-stimulation otherwise. Bootstrap resampling with 200 iterations, threshold sensitivity testing across exhaustion quantiles from 0.60 to 0.90, and weight sensitivity analysis confirmed ranking stability, with mean Spearman correlations above 0.85 and top-quartile patients retaining their position more than 90 percent of the time. Adjacent patients were separated by an average score gap of 0.03 normalized units, sufficient to avoid ambiguous recommendations.

The authors are candid about limitations. The pipeline was built and tested on a single cohort of 26 patients, exhaustion states were assigned by quantile-based gene-set scoring rather than experimental annotation, and the survival associations remain unadjusted for tumor purity, stage, and molecular subtype. The scoring weights are biologically motivated rather than data-trained, and no functional experiments have yet linked the recommendations to actual T cell activation outcomes. Future directions include integrating the spatial transcriptomics data that accompany the atlas to map where exhausted cells reside relative to tumor cells, training the score on labeled immunotherapy response cohorts, and connecting patient-level ratios to biophysical models of ligand density and clustering on synthetic cell membranes. As a prototype, the study demonstrates that single-cell immune phenotyping can be pushed beyond description into prescriptive design, offering synthetic immunologists a patient-specific starting point for building the engineered immune cells of tomorrow.

Subject of Research: A computational framework translating single-cell PDCD1/CD2 immune axis measurements into patient-specific synthetic immune cell engineering priorities for triple-negative breast cancer.

Article Title: Computational stratification and engineering framework of the PDCD1/CD2 immune axis in triple-negative breast cancer

Article References: Chowdhury, K. (2026). Computational stratification and engineering framework of the PDCD1/CD2 immune axis in triple-negative breast cancer. Clinical Cancer Bulletin, 5(1), Article 11. https://doi.org/10.1007/s44272-026-00063-5

Image Credits: AI Generated

DOI: 10.1007/s44272-026-00063-5

Keywords: triple-negative breast cancer, single-cell RNA sequencing, T cell exhaustion, PDCD1/CD2 axis, immune checkpoint blockade, synthetic immunology, tumor microenvironment, immune stratification, CD2/CD58 co-stimulation, DesignPriorityScore, TCGA-BRCA, ligand-receptor interactions